Visual contrast sensitivity in carbamazepine-resistant epileptic patients receiving vigabatrin as add-on therapy

Journal of Epilepsy

Volumn 10, Issue 1, 1997, Pages 7-11

  Sartucci, Ferdinando ^a   Massetani, Roberto ^b   Galli, Renato ^b   Bonanni, Enrica ^b   Tognoni, Gloria ^b   Milani, Silvano ^b   Iudice, Alfonso ^b   Murri, Luigi ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Carbamazepine; Epilepsy; Vigabatrin; Visual contrast sensitivity

Indexed keywords

CARBAMAZEPINE; VIGABATRIN;

ADULT; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; PRIORITY JOURNAL; VISUAL IMPAIRMENT;

EID: 0030900743     PISSN: 08966974     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6974(96)00065-5     Document Type: Article

References (29)

1. 1. Beghi F, Di Mascio R, Tognoni G. Drug treatment of epilepsy. Outlines, criticism and perspectives. Drugs 1986;31: 249-56.
2. 2. Bodis-Wollner I, Camisa JM. Contrast sensitivity in clinical diagnosis. In: Jassel S, van Dalen JIW, eds. Neuroophthalmology. Amsterdam: Elsevier, 1980:373-401.
3. 3. Kelly DH. Visual contrast sensitivity. Optica Acta 1977;24: 107-29.
4. 4. Domenici L, Trimarchi C, Piccolino M, Fiorentini A, Maffei L. Dopaminergic drugs improve human visual contrast sensitivity. Hum Neurobiol 1985;4:195-7.
5. 5. Tomson T, Nillsson BY, Levi R. Impaired visual contrast sensitivity in epileptic patients treated with carbamazepine. Arch Neurol 1988;45:897-900.
6. 6. Sartucci F, Domenici L. Contrast sensitivity measurements in clinical neurology. Ital J Clin Neurophysiol 1993;2:57-76.
7. 7. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27:43S-5S.
8. 8. Cocito L, Maffini M, Perfumo P, Roncallo F, Loeb C. Vigabatrin in complex partial seizures: a long-term study. Epilepsy Res 1989;3:160-6.
9. 9. Hammond EJ, Ballinger WE, Lu L, Wilder BJ, Uthman BM, Reid SA. Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res 1992;2:261-5.
10. 10. Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford JP, Perucca E. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27: 61S-8S.
11. 11. Arezzo JC, Schroeder CE, Litwak MS, Steward DL. Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol 1989;27:53S-60S.
12. 12. Zemon V, Kaplan E, Ratcliff F. The role of GABA-mediated intracortical inhibition in the generation of visual evoked potentials. In: Craine RQ, Body-Wollner I, eds. Evoked potentials. New York: Alan R. Liss, 1986:287-96.
13. 13. Krnjevic K. Significance of GABA in brain function. In: Tunnicliff G, Raess BU, eds. GABA mechanisms in epilepsy. New York: Wiley-Liss, 1991:47-87.
14. 14. SAS Institute Inc. SAS/STAT User's guide, 3rd ed. Cary, NC: SAS Institute, Inc., 1988.
15. 15. Murri L, Iudice A. Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients. Acta Neurol Scand 1995;92:40-2.
16. 16. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentials in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
17. 17. Riva R, Albani F, Ambrosetto G, Contin M, Cortelli P, Perucca E, Baruzzi A. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side-effects. Epilepsia 1984;25:476-81.
18. 18. Harris JP, Phillipson OT. Effects of lorazepam on human contrast sensitivity. Psychopharmacology 1995;117:379-84.
19. 19. Maffei L, Cervetto L, Fiorentini A. Transfer characteristics of excitation and inhibition in retinal ganglion cells. J Physiol 1970;2:276-84.
20. 20. Avoli M, Hwa GCG. GABA-mediated potentials and epileptogenesis. In: Avanzini G, Fariello R, Heinemann U, Mutani R, eds. Epileptogenic and Excitotoxic Mechanisms. London: John Libbey, 1993:51-8.
21. 21. MacDonald RL, Twyman RF, Jastrock TR, Angelotti TP. Regulation of GABA: A receptor channels by anticonvulsive and convulsant drugs and by phosphorylation. Epilepsy Res 1992;9(suppl):265-77.
22. 22. Bayer A, Zrenner E, Ried S, Schmidt D. Effects of a anticonvulsant drugs on retinal function. Psychophysical and electrophysiological findings in patients with epilepsy [Abstract]. Invest Visual Sci 1990;31:427.
23. 23. Chapman B, Stryker MP. Origin of orientation tuning in the visual cortex. Curr Opin Neurobiol 1992;2:498-501.
24. 24. Hubel DH. Single unit activity in lateral geniculate body and optic tract of unrestrained cats. J Physiol 1960;150:91-104.
25. 25. Crook JM, Eysel UT, MacHemer HF. Influence of GABA-induced remote inactivation on the orientation tuning of cells in area 18 of feline visual cortex: a comparison with area 17. Neuroscience 1991;40:1-12.
26. 26. Tsumoto TK, Eckart W, Creutzfeldt OD. Modification of orientation sensitivity of cat visual cortex neurones by removal of GABA-mediated inhibition. Exp Brain Res 1979;34:351-63.
27. 27. Kelly SA, Tomlinson A. Effect of repeated testing on contrast sensitivity. Am J Optom Physiol Opt 1987;64:241-5.
28. 28. Long GM, Penn DL. Normative contrast sensitivity functions: the problem of comparison. Am J Optom Physiol Opt 1987;64:131-5.
29. 29. Blin O, Mestre D, Paut O, Vercher JL, Audebert C. GABA-ergic control of visual perception in healthy volunteers: effects of midazolam, a benzodiazepine, on spatio-temporal contrast sensitivity. Br J Clin Pharmacol 1993;36:117-24.